Amgen Non-GAAP EPS of $5.00 beats by $0.51, revenue of $6.98B beats by $300M
Amgen press release  (NASDAQ:AMGN): Q2  Non-GAAP EPS of $5.00  beats by $0.51.
Revenue of $6.98B (+5.9% Y/Y)  beats by $300M.
2023 Guidance:
Total revenues in the range of $26.6 billion to $27.4 billionÂ vs. $27.32B consensus
On a GAAP basis, EPS in the range of $14.30 to $15.41, and a tax rate in the range of 17.0% to 18.5%.
On a non-GAAP basis, EPS in the range of $17.80 to $18.80 vs. $17.70 consensus, and a tax rate in the range of 17.5% to 18.5%.
Capital expenditures to be approximately $925 million.
Share repurchases not to exceed $500 million.